PSMA-CAR NK cell therapy (NantKwest)

N/A

Report date: 2025/03/20 15:43:26

Base Information

Drug NamePSMA-CAR NK cell therapy (NantKwest)

Drug Alias Nameanti-PSMA CAR NK-cell therapy (NantKwest)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunitybio Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunitybio Inc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A